PMID- 38351552
OWN - NLM
STAT- MEDLINE
DCOM- 20240215
LR  - 20240314
IS  - 2573-8348 (Electronic)
IS  - 2573-8348 (Linking)
VI  - 7
IP  - 2
DP  - 2024 Feb
TI  - Impaired monocyte-derived dendritic cell phenotype in prostate cancer patients: A 
      phenotypic comparison with healthy donors.
PG  - e1996
LID - 10.1002/cnr2.1996 [doi]
LID - e1996
AB  - BACKGROUND: Dendritic cells (DCs) play a crucial role in immunity. Research on 
      monocyte-derived DCs (Mo-DCs) cancer vaccines is in progress despite limited 
      success in clinical trials. This study focuses on Mo-DCs generated from prostate 
      cancer (PCA) patients, comparing them with DCs from healthy donors (HD-DCs). 
      METHODS: Mo-DCs were isolated from PCA patient samples, and their phenotype was 
      compared to HD-DCs. Key parameters included monocyte count, CD14 expression, and 
      the levels of maturation markers (HLA-DR, CD80, CD86) were assessed. RESULTS: PCA 
      samples exhibited a significantly lower monocyte count and reduced CD14 
      expression compared to healthy samples (p ⟨ 0.0001). Additionally, PCA-DCs 
      expressed significantly lower levels of maturation markers, including HLA-DR, 
      CD80, and CD86, when compared to HD-DCs (p = 0.123, p = 0.884, and p = 0.309, 
      respectively). CONCLUSION: The limited success of DC vaccines could be attributed 
      to impaired phenotypic characteristics. These observations suggest that 
      suboptimal characteristics of Mo-DCs generated from cancer patient blood samples 
      might contribute to the limited success of DC vaccines. Consequently, this study 
      underscores the need for alternative strategies to enhance the features of Mo-DCs 
      for more effective cancer immunotherapies.
CI  - (c) 2024 The Authors. Cancer Reports published by Wiley Periodicals LLC.
FAU - Bakhshi, Parisa
AU  - Bakhshi P
AD  - Department of Medical Biotechnology, School of Allied Medical Sciences, Iran 
      University of Medical Sciences, Tehran, Iran.
FAU - Nourizadeh, Maryam
AU  - Nourizadeh M
AD  - Immunology, Asthma and Allergy Research Institute, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Sharifi, Laleh
AU  - Sharifi L
AD  - Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, 
      Iran.
FAU - Nowroozi, Mohammad R
AU  - Nowroozi MR
AD  - Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, 
      Iran.
FAU - Mohsenzadegan, Monireh
AU  - Mohsenzadegan M
AUID- ORCID: 0000-0003-2434-9728
AD  - Department of Medical Laboratory Sciences, School of Allied Medical Sciences, 
      Iran University of Medical Sciences, Tehran, Iran.
FAU - Farajollahi, Mohammad M
AU  - Farajollahi MM
AD  - Department of Medical Biotechnology, School of Allied Medical Sciences, Iran 
      University of Medical Sciences, Tehran, Iran.
LA  - eng
GR  - 12937/Iran University of Medical Sciences/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Rep (Hoboken)
JT  - Cancer reports (Hoboken, N.J.)
JID - 101747728
RN  - 0 (B7-1 Antigen)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Vaccines)
SB  - IM
MH  - Humans
MH  - Male
MH  - Monocytes/metabolism
MH  - Cell Differentiation
MH  - Dendritic Cells/metabolism
MH  - B7-1 Antigen/metabolism
MH  - HLA-DR Antigens/metabolism
MH  - *Prostatic Neoplasms/therapy/metabolism
MH  - Phenotype
MH  - *Vaccines/metabolism
PMC - PMC10864738
OTO - NOTNLM
OT  - co-stimulatory molecules
OT  - dendritic cells
OT  - prostate cancer
COIS- The authors have stated explicitly that there are no conflicts of interest in 
      connection with this article.
EDAT- 2024/02/14 06:43
MHDA- 2024/02/15 06:43
PMCR- 2024/02/13
CRDT- 2024/02/14 00:43
PHST- 2024/01/20 00:00 [revised]
PHST- 2023/09/03 00:00 [received]
PHST- 2024/01/22 00:00 [accepted]
PHST- 2024/02/15 06:43 [medline]
PHST- 2024/02/14 06:43 [pubmed]
PHST- 2024/02/14 00:43 [entrez]
PHST- 2024/02/13 00:00 [pmc-release]
AID - CNR21996 [pii]
AID - 10.1002/cnr2.1996 [doi]
PST - ppublish
SO  - Cancer Rep (Hoboken). 2024 Feb;7(2):e1996. doi: 10.1002/cnr2.1996.